Key Takeaways Tempus AI gained FDA clearance for its ECG-Low EF tool, expanding its cardiology AI portfolio. A $200M deal with AZN and Pathos boosts TEM's role in building a major oncology foundation model. Hereditary testing revenue hit $63.5M, up 23% in volumes after Ambry Genetics' integration.Tempus AI (TEM) jumped 7.3% at yesterday’s close after securing FDA 510(k) clearance for its ECG-Low EF software, its second greenlighted AI tool in cardiology. The approval adds fuel to a stock already rallying ...